It reversibly binds to the ATP-binding site in the tyrosine kinase region of HER1 (EGFR) and HER2 cells, blocking downstream pathways, and thus inhibiting tumor growth(Bilancia et al. 2007; Johnston et al. 2021). This evidence concerns the gene ERBB2 and neoplasm.